Healthy person
Conditions
Interventions
Test group:Take orally, one tablet per day. Consume for 28 consecutive days.
Sponsors
Changsha Taihe Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years old, no gender restrictions; 2. At the time of screening, all the following conditions must be met for a period of 1 month or more: a office worker; b goes to bed after 11 p.m. at least 3 times per week, and the average total sleep time per single sleep session is less than 6 hours per night; 3. Can comply with and cooperate with the research requirements and voluntarily participate in the study.
Exclusion criteria
Exclusion criteria: 1. Individuals known to be allergic to more than two allergens; 2. Contraindications for exercise, such as hernia, prolapse, active hemorrhoids, previous retinal detachment, diabetic retinopathy, recent cataract surgery, aneurysm (especially abdominal aortic aneurysm) or uncontrolled hypertension (systolic blood pressure >= 180 mmHg); 3. Previous or current history of bleeding disorders, coagulation dysfunction (such as hereditary telangiectasia, various purpura, thrombocytopenia, intracranial hemorrhage, gastrointestinal bleeding, urinary tract bleeding, hemophilia, myeloproliferative syndromes, etc.); 4. Participants with serious diseases or disorders of important organs or systems such as heart, liver, lung, kidney, and blood system during the screening process, or malignant tumors; 5. Within 3 months before screening, having a history of surgery, major trauma (such as fractures, bone fractures, acute sprains, etc.), sports injuries, severe degenerative joint diseases; 6. No history of abnormal ovarian function or confirmed diseases; 7. Taking antioxidant agents, protein powder, creatine, and other sports nutrition supplements and other products containing PQQ within 1 month before screening; 8. Taking or expected to take antiplatelet drugs, anticoagulant drugs during the screening period or during the study; 9. Currently participating in other clinical trials; 10. Pregnant or lactating women participating in the study; 11. Other situations that the researcher deems unsuitable for participating in the clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The 1-RM and the number of effective completions for each group of actions before and after the use; | — |
Secondary
| Measure | Time frame |
|---|---|
| Use the total score of the Fatigue Scale - 14, the score of physical fatigue, and the score of mental fatigue;Use the subjective physical sensation rating scale during both pre- and post-exercise (RPE);Change in the total score of PSQI before and after use;Changes in pulse rate before and after exercise;Subjective facial aging assessment (rated separately on several dimensions including skin dryness, skin elasticity, skin luster, fine wrinkles, and skin smoothness);Use the pre- and post-memory quotient to measure the changes before and after.;Use the Kupperman Menopause Scale (modified Kupperman Menopause Scale) for assessment;Simple ovarian function score;Use the six items of sex hormones before and after the procedure;The peak levels of lactate before and after exercise;Adverse events, serious adverse events, their incidence rates, frequencies, and severity during the research period; | — |
Countries
China
Contacts
Public ContactTan Zhirong
Changsha Taihe Hospital
Outcome results
None listed